Navigation Links
Examination of lymph nodes provides more accurate breast cancer prognosis
Date:7/29/2013

After a breast cancer operation, the removed tumour is always examined, as its subtype can provide an indication of how aggressive the disease is. The patient's lymph nodes are not analysed in the same way. Yet the breast tumour can sometimes appear to be of a less aggressive type while the subtype in the lymph nodes gives a different and more worrying picture.

In these cases, it is the lymph nodes that provide the correct prognosis, according to new research at Lund University in Sweden. An analysis of the proliferation, hormone receptor status and HER2 status of the lymph nodes would in many cases show a significantly more accurate picture of the risk of metastases, i.e. a recurrence of the disease and its spreading to other organs.

"It would be easy to add such an analysis. It does not require any expensive specialist technology, but only an extension of the normal, routine pathology work", says Lisa Rydn, a consultant surgeon and researcher at Lund University.

The study covers 500 women in the early stages of breast cancer who underwent surgery in Lund or Helsingborg. Early-stage breast cancer is when the cancer has not yet spread to other organs. However, in approximately one third of all the women who underwent surgery for early-stage breast cancer, there were traces of the tumour in the lymph nodes, which can provide important additional information.

"Sometimes the molecular study showed the same subtype in the breast tissue and in the lymph nodes. But sometimes the types were different. And when we investigated the outcomes for the women 10 years later, the prognosis followed the subtype that was present in the lymph nodes and not the one in the breast", says Lisa Rydn.

Thus when doctors only examine the breast tissue, there is a risk that the tumour will be found to be of a low-risk type, which affects decisions on further treatment. The lymph nodes may meanwhile show signs of a more aggressive form of tumour, but that is never discovered.

"If, on the other hand, we start routinely analysing the lymph nodes as well, we can treat women in such cases with additional cytostatic and targeted drugs after their operation. This could prevent later recurrence of the disease" thinks Lisa Rydn.

A fairly small proportion of the patients in the study showed a difference in tumour type between the breast tissue and the lymph nodes. But since breast cancer is such a common disease, the number of patients affected nationally and globally will still be considerable and, for them, the difference can be that between life and death, the Lund researcher points out.


'/>"/>

Contact: Lisa Rydén
lisa.ryden@med.lu.se
46-706-720-923
Lund University
Source:Eurekalert

Related medicine news :

1. North American Seminars Receives NY State Approval for a New Physical Therapy Online Continuing Education Course, Examination and Treatment of the SI Joint
2. North American Seminars Introduces a New Online Continuing Education Course for Physical Therapists, Examination and Treatment of the Hip Joint
3. North American Seminars Introduces Vestibular Rehabilitation - Examination and Treatment, a New Physical Therapy Online Continuing Education Course
4. North American Seminars Introduces a New Online Continuing Education Course for Physical Therapists, Examination and Treatment of the SI Joint
5. Sharing examination questions threatens trust in medical profession
6. Report offers an in-depth examination of health centers role in family planning
7. Decision support system translates into high percentage of positive chest CT examinations
8. HIV-associated lymphoma survival has not improved during the antiretroviral therapy era
9. North Shore-LIJ Health System's Feinstein Institute to Receive $250,000 Grant from Lymphoma Research Foundation Grant to support research of Chronic Lymphocytic Leukemia
10. Innovative Technique Seeks to Prevent Lymphedema in Breast Cancer Patients
11. Radioimmunotherapy deemed safe and effective for lymphoma patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2017)... SALISBURY, MD. (PRWEB) , ... June 26, 2017 ... ... their crop, according to a recent review of government data released by the ... continuous improvement in management practices, Maryland’s soybean farmers have increased their productivity on ...
(Date:6/26/2017)... Tahoe, CA (PRWEB) , ... June 26, 2017 , ... ... 10,000 qualified mental health professionals in every state across the country to join its ... easy and rewarding way for therapists to reach a substantially greater number of people ...
(Date:6/26/2017)... Moscow, RU (PRWEB) , ... June 26, 2017 , ... ... released a whitepaper that pledges to solve many catastrophic issues within funding ... September 2017. , The typical notion of crowdfunding - the raising of funds through ...
(Date:6/25/2017)... , ... June 25, 2017 , ... FCPX LUT Vintage ... an old-fashioned vintage look. FCPX LUT Vintage Volume 2 contains 60 different color-grade presets, ... for distorted looks, vignettes and blurs to single out subjects, plus much more. FCPX ...
(Date:6/25/2017)... ... 2017 , ... Republicans in the United States Senate on Thursday released their ... Reconciliation Act. It differs significantly from the American Health Care Act, which the House ... or the House will have to take up the Senate version as-is, if it ...
Breaking Medicine News(10 mins):
(Date:6/16/2017)...  Exactly 50 years ago today, the Monterey Pop Festival ... as the San Francisco "Summer of Love."  To celebrate the ... innovations in strategic market research portals that it will begin ... of Northern Light,s "Summer of Love (For Our Customers)."  ... ...
(Date:6/14/2017)...  In 2016, Embodied Labs took top ... and came away with $25,000 in seed-fund investment. Embodied ... as "entering the life of another" and by the ... to medical professionals in an entirely new dimension." Building ... finalist for the Department of Education,s EdSimChallenge, where they ...
(Date:6/11/2017)... , June 10, 2017  Eli Lilly and Company (NYSE: ... three Phase 3 studies of galcanezumab, an investigational treatment ... late-breaking data on several key secondary endpoints for galcanezumab ... from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be ... scientific meeting in Boston . ...
Breaking Medicine Technology: